GleamWall
中文EN

VOR Vor Biopharma Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY155.3%
TTM EPS YoY177.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA402.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets127.6%
Debt / equity—
Current ratio13.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.09x
Accruals ratio438.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$34.53M$25.92M$17.59M$19.19M$14.14M$261.50M$26.70M$25.35M
SG&A expense$23.91M$21.93M$17.57M$16.77M$13.96M$12.79M$6.59M$5.96M
Operating income-$58.44M-$47.85M-$35.16M-$35.96M-$28.11M-$274.28M-$33.29M-$31.31M
Net income-$86.73M-$62.81M-$219.58M$1.72B-$812.68M-$1.57B-$32.49M-$30.71M
EBITDA-$58.41M-$47.82M-$35.13M-$35.94M-$26.01M-$272.18M-$32.47M-$30.45M
EPS (basic)-1.45-1.16-5.11—-121.63-251.24-5.21—
EPS (diluted)-1.45-1.16-5.11—-121.63-251.24-5.21—
Weighted avg. shares (diluted)59.67M54.30M43.01M—6.68M6.26M6.24M—
Balance sheet
Cash & equivalents$78.98M$107.86M$169.87M$396.49M$160.46M$190.57M$50.05M$81.95M
Short-term investments$402.57M$358.27M$321.65M$58.72M$10.00M$9.99M$9.99M$9.98M
Current assets$490.52M$475.11M$500.78M$458.11M$172.49M$204.93M$64.85M$96.51M
PP&E, net$623,000$648,000$565,000$533,000$271,000$0$5.99M$6.58M
Total assets$496.31M$481.05M$506.75M$464.13M$176.24M$205.37M$109.31M$142.89M
Current liabilities$36.34M$24.81M$16.08M$25.17M$18.84M$58.77M$16.73M$18.61M
Total liabilities$633.49M$681.25M$657.17M$628.44M$2.40B$1.71B$43.24M$46.23M
Shareholders' equity-$137.17M-$200.20M-$150.42M-$164.31M-$2.23B-$1.51B$66.07M$96.66M
Shares outstanding61.43M54.46M54.19M38.72M9.03M125.65M124.85M6.24M
Cash flow statement
Operating cash flow-$32.75M-$25.38M-$38.25M-$22.80M-$53.66M-$35.18M-$31.07M-$24.06M
Capital expenditure$25,000$120,000$48,000$314,000$244,000$152,000$231,000$72,000
Free cash flow-$32.77M-$25.50M-$38.29M-$23.11M-$53.91M-$35.34M-$31.30M-$24.14M
Investing cash flow-$44.78M-$36.53M-$263.24M-$48.97M-$244,000$646,000-$230,000-$72,000
Financing cash flow$48.65M-$106,000$74.87M$307.80M$21.55M$175.06M-$606,000$53.29M
Depreciation & amortization$39,000$36,000$28,000$23,000$2.10M$2.10M$825,000$865,000
Stock-based compensation$9.94M$9.40M$8.87M$7.11M$8.03M$1.84M$1.93M$1.71M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.